Escapelle® & Postinor-2® (levonorgestrel): Levonorgestrel-containing emergency hormonal contraception ─ New advice for users of hepatic-enzyme inducers

Kadar pengguna: 3 / 5

bintang aktifbintang aktifbintang aktifBintang tidak aktifBintang tidak aktif
 

Date: 15 March 2017

 

Description:

The metabolism of levonorgestrel is known to be increased by concomitant use of liver enzyme inducers, mainly inducers of CYP3A4 enzymes. This resulting reduction in plasma levonorgestrel levels may reduce contraceptive efficacy of levonorgestrel-containing emergency hormonal contraceptives. Women seeking emergency contraception who have used an enzyme-inducing medicine within the last 4 weeks are advised to use a non-hormonal emergency contraceptive, i.e. a copper intrauterine device (Cu-IUD). If this is not an option, they should be advised to double the usual dose of levonorgestrel from 1.5 mg to 3 mg to compensate for the reduction in plasma levonorgestrel levels. The information on the medicine’s outer carton and package insert is being revised to include the new dosing instructions for this category of women. For further details on this updated advice, please refer to the Direct Healthcare Professional Communication (DHPC) issued by Pahang Pharmacy Sdn. Bhd. in agreement with NPRA.

 

 

National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia.
  • Email: npra@npra.gov.my
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Site Last Modified

  • Last Modified: Isnin 13 Julai 2020, 15:17:00.
© Copyright 2019 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA

Choose Your Language